- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01766297
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy.
This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to compare the results (good or bad) of proton radiation therapy.
Study Overview
Status
Intervention / Treatment
Detailed Description
Current standard of care for early stage breast cancer is mastectomy or breast conserving therapy with whole breast irradiation following lumpectomy. However, studies of breast cancer recurrence have demonstrated the majority of tumors to recur in or adjacent to the original tumor site. The question has thus been raised as to whether radiation to the whole breast is necessary or justified. Limiting radiation to the area of the original tumor may reduce acute and long-term skin and organ toxicities while making radiation therapy more convenient and less expensive. Several clinical trials are underway comparing partial breast irradiation (PBI) to whole breast irradiation. Numerous centers are offering partial breast irradiation outside of clinical trials as well, despite the lack of long-term safety and efficacy data on PBI.
Available PBI methods include brachytherapy, in which catheters or balloons are surgically inserted to deliver radiation therapy to the lumpectomy cavity, and conventional external beam radiation therapy, or EBRT. External beam photon therapy is attractive for its non-invasive nature and ability to deliver a more homogenous dose distribution compared to brachytherapy, however it also delivers a greater radiation dose to surrounding normal breast tissue.Proton therapy has the capacity to provide the same advantages as photon EBRT while minimizing dose to normal surrounding tissue. Clinical data on PBI with protons is minimal, however, leaving many questions unanswered. The impetus behind this protocol is to address these gaps by further investigating the feasibility, safety, and efficacy of proton therapy for partial breast irradiation.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Matthew Morocco
- Phone Number: 630-836-8670
- Email: mmorocco@pcgresearch.org
Study Contact Backup
- Name: Edith Maritato
- Phone Number: 630-836-8668
- Email: emaritato@pcgresearch.org
Study Locations
-
-
California
-
San Diego, California, United States, 92121
- Recruiting
- California Protons Cancer Therapy Center
-
Contact:
- Alexandra Crawford, MPH
- Phone Number: 858-549-7431
- Email: alexandra.crawford@californiaprotons.com
-
Principal Investigator:
- James Urbanic, MD
-
-
Illinois
-
Warrenville, Illinois, United States, 60555
- Recruiting
- Northwestern Medicine Chicago Proton Center
-
Contact:
- Don Smith, MS, CCRC
- Phone Number: 630-933-7820
- Email: donald.smith3@nm.org
-
Principal Investigator:
- Arpi Thukral, MD
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- Maryland Proton Treatment Center
-
Contact:
- Caitlin Eggleston
- Phone Number: 410-328-7586
- Email: caitlineggleston@umm.edu
-
Principal Investigator:
- Elizabeth Nichols, MD
-
-
Michigan
-
Flint, Michigan, United States, 48532
- Recruiting
- McLaren Proton Therapy Center
-
Principal Investigator:
- Christian Hyde, MD
-
Contact:
- Bradley Olsen
- Phone Number: 313-576-9730
- Email: olsenb@karmanos.org
-
-
New York
-
New York, New York, United States, 10035
- Recruiting
- New York Proton Center
-
Contact:
- Ryan Holder
- Phone Number: 387 646-968-9055
- Email: rholder@nyproton.com
-
Principal Investigator:
- Isabelle Choi, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73142
- Recruiting
- Oklahoma Proton Center
-
Contact:
- Jenny Washington, BSRT(T), CMD
- Phone Number: 405-773-6700
- Email: jenny.washington@okcproton.com
-
Principal Investigator:
- John Chang, MD
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Inova Schar Cancer Institute
-
Contact:
- Sangeetha Moturi
- Phone Number: 571-472-0343
- Email: sangeetha.moturi@inova.org
-
Principal Investigator:
- Ashish Chawla, MD
-
Hampton, Virginia, United States, 23666
- Recruiting
- Hampton University Proton Therapy Institute
-
Contact:
- Donna Sternberg, RN, BSN, OCN
- Phone Number: 757-251-6839
- Email: donna.sternberg@hamptonproton.org
-
Principal Investigator:
- Christopher Sinesi, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must sign study-specific, IRB approved informed consent form prior to study entry. Note consent by legally authorized representative is not allowed for this trial.
- Must be female.
- Must be > = 50 years of age.
- Must have a life expectancy of at least 5 years based on age and co-morbidities.
- Must have pathology proven invasive ductal carcinoma (lobular is not allowed) and/or ductal carcinoma in situ (DCIS).
- One of the following criteria must be met: (a) Tumors that are microscopically multifocal must be 3.0 cm or less in total aggregate size and encompassed within a single scar (b) Patient does not have microscopically multifocal tumor.
- For tumors that are invasive, if in the presence of extensive intraductal component (EIC), the entire pathologic tumor size (including both the intraductal and invasive component) must be 3.0 cm or less.
- Must be Stage 0, I, II (Tis, T1, or T2, N0, M0 per AJCC criteria 7th and/or 8th Ed.). If stage II, the tumor size must be < = 3.0 cm. A patient with invasive histology must have nodal stage pN0 by H&E stains on sentinel node biopsy or axillary lymph node dissection.
- Must have ER positive disease with ER/PR report available.
- For tumors that are invasive, HER2 must be performed (positive or negative is acceptable).
- Must have a lumpectomy performed, with documented negative surgical margins by 0.2 cm or more. If re-excision results in negative surgical margins 0.2 cm or more, patient is eligible.
If image guidance with daily cone beam CT with direct physician visual assessment is used for treatment positioning, the presence of markers or clips in the surgical bed is recommended but not required. If cone beam CT imaging will NOT be used for image guidance, then the patient must be prepared to have 2 fiducial markers minimum, 3 preferred, placed prior to treatment (if not previously done).
- If markers or clips were placed at the time of surgery, patient must be able to start treatment within 12 weeks after lumpectomy or re-excision for adequate margins.
- If markers were not placed at the time of surgery and are needed, patient must have markers placed within 6 weeks after surgery.
- If systemic chemotherapy was given, patient must have had clips or markers placed at the time of surgery (if they are needed) and patient must have simulation scans within 6 weeks of the completion of the chemotherapy.
- Must be able to start treatment within 12 weeks of surgery or 8 weeks of finalization of chemotherapy.
Exclusion Criteria:
- Previous history of ipsilateral invasive breast cancer or DCIS.
- Any clinical or radiographically suspicious nodes, unless biopsy proven benign.
- Non-epithelial malignancies such as sarcoma or lymphoma.
- Suspicious residual microcalcifications on mammography of either breast, unless negative for malignancy on pathology.
- Multicentric or bilateral disease unless biopsy of the clinical abnormalities are performed and result is negative.
- Lymphovascular space invasion (LVSI) on pathology specimen.
- Any previously treated breast carcinoma or synchronous breast carcinoma in ipsilateral breast.
- Prior radiation therapy to the ipsilateral breast or thorax.
- Paget's disease of the nipple.
- Histologic examination showing invasive lobular histology.
- Skin involvement.
- Breasts technically unsatisfactory for radiation treatment upon the discretion of the treating physician.
- Significant infection or other co-existing medical condition that would preclude protocol therapy such as pregnancy, HIV/AIDS or collagen vascular diseases specifically systemic lupus erythematosus, scleroderma, or dermatomyositis.
- Known BRCA 1 or BRCA 2 mutation.
- Pregnant or lactating.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Proton Radiotherapy
Proton Radiotherapy 4.0 Gy (RBE) x10 fractions to 40 Gy (RBE) Total Dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess events of freedom from ipsilateral breast recurrence occurrences in patients receiving partial breast proton radiation therapy limited to the region of the tumor.
Time Frame: At 3 years
|
Freedom from failure (FFF): The events for FFF will be the first ipsilateral breast cancer recurrence.
It is expected that less than 3% of patients will experience an ipsilateral breast cancer recurrence (FFF ≥ 97%).
A recurrence rate of ≥ 10% (FFF ≤ 90%) is considered unacceptable.
Therefore, the null hypothesis is the FFF of ipsilateral breast cancer recurrence is 90% or lower and the alternative hypothesis is that FFF of ipsilateral breast cancer is 97% or higher.
|
At 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess number and severity of acute and long-term toxicity of partial breast irradiation using proton therapy for the treatment of early stage breast cancer.
Time Frame: On average every 6 months for life
|
On average every 6 months for life
|
To assess relationship between breast size and partial breast dosimetry.
Time Frame: Average every 6 months for 3 years
|
Average every 6 months for 3 years
|
Determine quality of life results.
Time Frame: Average every 6 months for 3 years
|
Average every 6 months for 3 years
|
To determine overall survival rate of patients with breast cancer treated with proton radiation.
Time Frame: At 3 years
|
At 3 years
|
To determine recurrence pattern of patients with breast cancer treated with proton partial breast irradiation.
Time Frame: At 3 years
|
At 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Andrew Chang, MD, Proton Collaborative Group
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BRE007-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Proton Radiotherapy
-
Massachusetts General HospitalNational Cancer Institute (NCI); Dana-Farber Cancer InstituteActive, not recruitingAstrocytoma | Brain Tumor | Ependymoma | Ganglioglioma | Low Grade GliomaUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Massachusetts General HospitalCompleted
-
Uppsala UniversityKarolinska University Hospital; Sahlgrenska University Hospital, Sweden; University... and other collaboratorsRecruitingArteriovenous Malformation | Central Nervous System TumourSweden
-
Proton Collaborative GroupActive, not recruitingBreast Cancer | Breast Neoplasm | Breast Tumor | Cancer of the BreastUnited States
-
Loma Linda UniversityActive, not recruiting
-
University of AarhusCentre Leon Berard; University College London Hospitals; Aarhus University Hospital and other collaboratorsRecruitingEsophageal Cancer | Radiotherapy | Proton Therapy | Side EffectUnited Kingdom, France, Belgium, Denmark, Germany, Italy, Netherlands, Switzerland
-
Washington University School of MedicineRecruitingMetastatic Cancer | Unresectable Solid TumorUnited States
-
Centre Francois BaclesseNational Cancer Institute, FranceNot yet recruitingCognitive Impairment | Cavernous Sinus Meningioma | Proton-therapy | Photon RadiotherapyFrance
-
National Cancer Center, KoreaCompletedHepatocellular CarcinomaKorea, Republic of